Stool Donor Body Mass Index Does Not Affect Recipient Weight After a Single Fecal Microbiota Transplantation for Clostridium difficile Infection

Fischer, Monika; Kao, Dina; Kassam, Zain; Smith, Justin D.; Louie, Thomas; Sipe, Brian; Torbeck, Michelle; Xu, Huiping; Ouyang, Fangqian; Mozaffarian, Dariush; Allegretti, Jessica R.

doi:10.1016/j.cgh.2017.12.007

Cited by 21 publications

(18 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A widely-reported case study noted apparent weight gain in a recipient of FMT for treatment of CDI when an overweight donor was used,91 but any association between a donor with a raised BMI and weight gain post-FMT has not been replicated elsewhere in the literature 92. Whereas most randomised studies did not report donor-specific BMIs, some have excluded those without a ‘normal’ BMI 13 17.…”

Section: Rationale For Recommendationsmentioning

confidence: 99%

The use of faecal microbiota transplant as treatment for recurrent or refractoryClostridium difficileinfection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

Mullish

Quraishi

Segal

et al. 2018

Gut

273

187

View full text Add to dashboard Cite

Interest in the therapeutic potential of faecal microbiota transplant (FMT) has been increasing globally in recent years, particularly as a result of randomised studies in which it has been used as an intervention. The main focus of these studies has been the treatment of recurrent or refractory infection (CDI), but there is also an emerging evidence base regarding potential applications in non-CDI settings. The key clinical stakeholders for the provision and governance of FMT services in the UK have tended to be in two major specialty areas: gastroenterology and microbiology/infectious diseases. While the National Institute for Health and Care Excellence (NICE) guidance (2014) for use of FMT for recurrent or refractory CDI has become accepted in the UK, clear evidence-based UK guidelines for FMT have been lacking. This resulted in discussions between the British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS), and a joint BSG/HIS FMT working group was established. This guideline document is the culmination of that joint dialogue.

show abstract

Section: Rationale For Recommendationsmentioning

confidence: 99%

The use of faecal microbiota transplant as treatment for recurrent or refractoryClostridium difficileinfection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

Mullish

Quraishi

Segal

et al. 2018

Gut

273

187

View full text Add to dashboard Cite

show abstract

“…In addition, transmission of malignant, metabolic and neuropsychiatric disorders has been shown in animal models 42‐44 . In contrast, Fischer et al 45 reported that there was no effect of donor's body mass index on recipients’ weight after a single GMT for recurrent C difficile infection, suggesting that obesity phenotype may not be transmissible. Thus, in the evaluation of the most suitable donor for treatment of obesity and metabolic diseases, rigorous screening and careful consideration of the donor's medical conditions including weight appear to be extremely vital.…”

Section: Who Is a Healthy Donor?mentioning

confidence: 99%

Gut microbiome transfer—Finding the perfect fit

Leong

O’Sullivan

Derraik

et al. 2020

Clinical Endocrinology

View full text Add to dashboard Cite

Gut microbiome transfer (GMT; also referred to as faecal microbiota transplantation or FMT) has been propelled from fringe therapy to mainstream science as a highly effective treatment for recurrent Clostridioides difficile infection. As a result, there has been great interest in the potential efficacy and safety of GMT in treating other medical conditions, for example inflammatory bowel disease, and more recently as a novel therapy for obesity and metabolic diseases. For these chronic conditions, the results from clinical trials have been mixed. Further, specifically in obesity and metabolic diseases, there are limited available data, with only a few published studies with a small number of participants and short duration of follow‐up. Therefore, this review aims to explore the human, microbial and formulation factors that may affect the success of GMT. This includes various aspects in the preparation and administration of GMT, such as stool processing, modes of delivery, pretreatment with antibiotics and/or bowel lavage, frequency of GMT and possible use of precision bacteriotherapy. In addition, we examine the potential use of GMT in obesity, type 2 diabetes and metabolic diseases based on current available literature, highlighting some recent advances in GMT research in this area, as well as potential adverse effects after GMT therapy.

show abstract

“…179 FMT from lean donors does not appear to reduce the BMI of overweight recipients. [181][182][183] Very limited human data is currently available regarding the impact of FMT on NAFLD. Craven et al 184 found that FMT from slim healthy donors to individuals with NAFLD did not affect hepatic steatosis or insulin sensitivity but did reduce gut permeability.…”

Section: The Gut Microbiome As a Therapeutic Target In Nafldmentioning

confidence: 99%

The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease

Jennison

Byrne

2021

Clin Mol Hepatol

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, with a prevalence that is increasing in parallel with the global rise in obesity and type 2 diabetes mellitus. The pathogenesis of NAFLD is complex and multifactorial, involving environmental, genetic and metabolic factors. The role of the diet and the gut microbiome is gaining interest as a significant factor in NAFLD pathogenesis. Dietary factors induce alterations in the composition of the gut microbiome (dysbiosis), commonly reflected by a reduction of the beneficial species and an increase in pathogenic microbiota. Due to the close relationship between the gut and liver, altering the gut microbiome can affect liver functions; promoting hepatic steatosis and inflammation. This review summarises the current evidence supporting an association between NAFLD and the gut microbiome and dietary factors. The review also explores potential underlying mechanisms underpinning these associations and whether manipulation of the gut microbiome is a potential therapeutic strategy to prevent or treat NAFLD.

show abstract

Stool Donor Body Mass Index Does Not Affect Recipient Weight After a Single Fecal Microbiota Transplantation for Clostridium difficile Infection

Cited by 21 publications

References 6 publications

The use of faecal microbiota transplant as treatment for recurrent or refractoryClostridium difficileinfection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

The use of faecal microbiota transplant as treatment for recurrent or refractoryClostridium difficileinfection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

Gut microbiome transfer—Finding the perfect fit

The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease

Contact Info

Product

Resources

About